Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation

• Metastatic CSMD3 mutated HGSOC showed objective and sustained response to pembrolizumab. • The tumor was massively infiltrated by CD8(+) T cells while PD-L1 TPS was at 10%. • CSMD3 mutated HGSOC showed up-regulation of CCL5 and CXCL9.

Detalles Bibliográficos
Autores principales: Terzic, Julie, Seipel, Amanda, Dubuisson, Jean, Tille, Jean-Christophe, Tsantoulis, Petros, Addeo, Alfredo, Labidi-Galy, S.Intidhar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7322246/
https://www.ncbi.nlm.nih.gov/pubmed/32613071
http://dx.doi.org/10.1016/j.gore.2020.100600
_version_ 1783551607907024896
author Terzic, Julie
Seipel, Amanda
Dubuisson, Jean
Tille, Jean-Christophe
Tsantoulis, Petros
Addeo, Alfredo
Labidi-Galy, S.Intidhar
author_facet Terzic, Julie
Seipel, Amanda
Dubuisson, Jean
Tille, Jean-Christophe
Tsantoulis, Petros
Addeo, Alfredo
Labidi-Galy, S.Intidhar
author_sort Terzic, Julie
collection PubMed
description • Metastatic CSMD3 mutated HGSOC showed objective and sustained response to pembrolizumab. • The tumor was massively infiltrated by CD8(+) T cells while PD-L1 TPS was at 10%. • CSMD3 mutated HGSOC showed up-regulation of CCL5 and CXCL9.
format Online
Article
Text
id pubmed-7322246
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-73222462020-06-30 Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation Terzic, Julie Seipel, Amanda Dubuisson, Jean Tille, Jean-Christophe Tsantoulis, Petros Addeo, Alfredo Labidi-Galy, S.Intidhar Gynecol Oncol Rep Case Report • Metastatic CSMD3 mutated HGSOC showed objective and sustained response to pembrolizumab. • The tumor was massively infiltrated by CD8(+) T cells while PD-L1 TPS was at 10%. • CSMD3 mutated HGSOC showed up-regulation of CCL5 and CXCL9. Elsevier 2020-06-15 /pmc/articles/PMC7322246/ /pubmed/32613071 http://dx.doi.org/10.1016/j.gore.2020.100600 Text en © 2020 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Terzic, Julie
Seipel, Amanda
Dubuisson, Jean
Tille, Jean-Christophe
Tsantoulis, Petros
Addeo, Alfredo
Labidi-Galy, S.Intidhar
Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation
title Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation
title_full Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation
title_fullStr Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation
title_full_unstemmed Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation
title_short Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation
title_sort sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with csmd3 mutation
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7322246/
https://www.ncbi.nlm.nih.gov/pubmed/32613071
http://dx.doi.org/10.1016/j.gore.2020.100600
work_keys_str_mv AT terzicjulie sustainedresponsetopembrolizumabwithoutpriorchemotherapyinhighgradeserousovariancarcinomawithcsmd3mutation
AT seipelamanda sustainedresponsetopembrolizumabwithoutpriorchemotherapyinhighgradeserousovariancarcinomawithcsmd3mutation
AT dubuissonjean sustainedresponsetopembrolizumabwithoutpriorchemotherapyinhighgradeserousovariancarcinomawithcsmd3mutation
AT tillejeanchristophe sustainedresponsetopembrolizumabwithoutpriorchemotherapyinhighgradeserousovariancarcinomawithcsmd3mutation
AT tsantoulispetros sustainedresponsetopembrolizumabwithoutpriorchemotherapyinhighgradeserousovariancarcinomawithcsmd3mutation
AT addeoalfredo sustainedresponsetopembrolizumabwithoutpriorchemotherapyinhighgradeserousovariancarcinomawithcsmd3mutation
AT labidigalysintidhar sustainedresponsetopembrolizumabwithoutpriorchemotherapyinhighgradeserousovariancarcinomawithcsmd3mutation

Ejemplares similares